Abigail A. Mornement

Abigail A. Mornement

Auto-generated profile, based on publicly available information

Abigail A. Mornement

CHARM Therapeutics Ltd., B900, Babraham Research Campus, Cambridge, UK

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
CFCatherine T. Fletcher
Catherine T. Fletcher
AMAbigail A. Mornement
Abigail A. Mornement
CBCharlotte Barrett
Charlotte Barrett
PCPeter Canning
Peter Canning
PRPrakash Rucktooa
Prakash Rucktooa
AKAmanda J. Kennedy
Amanda J. Kennedy
Werner syndrome helicase (WRN) is a RecQ-family DNA helicase essential for genome maintenance and is a synthetic lethal target in microsatellite instability-high (MSI-H) cancers. Despite its therapeutic promise, the conformational dynamics that enable WRN to unwind DNA, and how inhibitors disrupt this activity, remains poorly understood. Here, we present crystal structures of apo WRN and WRN bound to single-stranded DNA (ssDNA), capturing key conformations in the helicase catalytic cycle. These structures reveal how WRN engages DNA through conserved polar and aromatic interactions, and how domain rearrangements, including an ordering of the aromatic-rich loop (ARL), drive directional translocation. Biochemical and biophysical data demonstrate how nucleotide and inhibitor binding remodel these conformations and suggest that known clinical inhibitors (HRO761 and VVD-133214) function by locking WRN in inactive, ‘off-DNA’ states. Resistance emerged rapidly in vitro, through acquired point mutations as well as altered WRN expression. Together, our findings provide a structural framework for the WRN structural cycle and support the development of next-generation ‘on-DNA’ inhibitors to overcome resistance.